{"id":"NCT03999996","sponsor":"Takeda","briefTitle":"Long-Term Safety and Antibody Persistence of TDV and the Impact of a Booster Dose","officialTitle":"A Phase 3, Follow-Up Trial to Evaluate Long-Term Safety and Antibody Persistence, and the Impact of a Booster Dose of a Tetravalent Dengue Vaccine Candidate in Healthy Adolescents and Adults in Areas Non-Endemic for Dengue","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-11-12","primaryCompletion":"2024-05-25","completion":"2024-05-25","firstPosted":"2019-06-27","resultsPosted":"2025-06-12","lastUpdate":"2025-06-12"},"enrollment":365,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Dengue Fever"],"interventions":[{"type":"BIOLOGICAL","name":"Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV)","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Prior to Booster: DEN-304","type":"EXPERIMENTAL"},{"label":"Prior to Booster: DEN-315","type":"EXPERIMENTAL"},{"label":"Booster Phase: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Booster Phase: TDV","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to describe antibody persistence for each of the 4 dengue serotypes for up to 63 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-315 (NCT03341637) (Mexico) and for up to 36 months after the first vaccination in the primary vaccination series for participants from parent trial DEN-304 (NCT03423173) (United States \\[US\\]) and to describe the impact of a tetravalent dengue vaccine (TDV) booster dose vs placebo on antibody response for each of the 4 dengue serotypes at 1 month and 6 months post administration of the TDV booster or placebo.","primaryOutcome":{"measure":"Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes in the Period Prior to Booster at Visit 1 (Month 0 [Day 1])","timeFrame":"Month 0 (Day 1)","effectByArm":[{"arm":"Prior to Booster: DEN-304","deltaMin":76.8,"sd":null},{"arm":"Prior to Booster: DEN-315","deltaMin":88.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["United States","Mexico"]},"refs":{"pmids":["40099800"],"seeAlso":["https://clinicaltrials.takeda.com/study-detail/5f6b603c4db2bf003ab4a33e?idFilter=%5B%22DEN-303%22%5D"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":246},"commonTop":["Pain","Headache","Myalgia","Malaise","Asthenia"]}}